The Impact of Dementia Development Concurrent with Parkinson’s Disease: A New Perspective

E-ISSN： 1996-3181|13|7|1160-1168

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.13, Iss.7, 2014-09, pp. : 1160-1168

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease

Current Medicinal Chemistry, Vol. 23, Iss. 4, 2016-02 ,pp. : 346-359

Bentham Science Publishers

Access to resources Recommend Favorite

Neuroprotection for Parkinson’s disease: a new approach for a new millennium

By Drukarch Benjamin van Muiswinkel Freek L

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 10, 2001-10 ,pp. : 1855-1868

Informa Healthcare

Access to resources Recommend Favorite

Entacapone in the management of Parkinson’s disease

By Waters Cheryl Henchcliffe Claire

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 957-963

Informa Healthcare

Access to resources Recommend Favorite

Dopaminergic substitution in Parkinson’s disease

By Müller Thomas

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 10, 2002-10 ,pp. : 1393-1403

Informa Healthcare

Access to resources Recommend Favorite

Dopamine agonists in Parkinson’s disease

By Tintner Ron Jankovic Joseph

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 11, 2003-11 ,pp. : 1803-1820

Informa Healthcare

Access to resources Recommend Favorite